Vir Biotechnology, Inc. today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback